Hanmi Pharma’s Oraxol receives priority review designation from US FDA
Author : Saipriya Iyer | Published Date : 2020-09-03
Hanmi Pharmaceuticals, a renowned South Korean pharmaceutical firm, has reportedly announced that its new oral anticancer drug, Oraxol, has been assigned the priority review designation by the United States Food and Drug Administration (US FDA).
Speaking on the same, Athenex, partner of Hanmi stated that with the FDA accepting the application review for marketing authorization to treat NDA (metastatic breast cancer), priority review was designated to Axol.
The ‘Priority Review’ system of the FDA decides whether to approve new drugs or not in less than 6 months. It is reserved for drugs that can substantially enhance the safety and efficacy in the diagnosis, treatment, and prevention of critical diseases. The normal screening process generally takes 10 months to complete.
In accordance with the PDUFA (Prescription Drug User Fee Act), the FDA aims to finish the AXOL review of marketing authorization by February 2021.
CMO of Athenex, Rudolph Kwan stated that the company is actively working on priority review with the US FDA in order to offer the medication to patients suffering from metastatic breast cancer as early as possible. The firm plans to continue its investments towards expanding the reach and use of the oral drug.
The review application for Axol was submitted on the basis of outcomes of phase 3 clinical trial in comparison with the efficacy and safety monotherapy and paclitaxel monotherapy in patients diagnosed with metastatic breast cancer. The trial’s primary endpoint, objective response rate (ORR), was enhanced to a significant point in Rexol in comparison with the intravenous paclitaxel, as well as the neuropathy incidence was also relatively low.
Hanmi Pharma’s ‘ORASCOVERY’ platform technology, which transforms the anticancer drugs used for injections to be used for oral therapy was implemented for AXOL. In 2018, Rexol was given the designation of the orphan drug to treat hemangiosarcoma by the FDA. The drug was also approved by European EMA in 2019 to treat soft tissue sarcoma.
Source credit: https://www.en24news.com/2020/09/fda-designates-hanmi-pharmaceuticals-anticancer-drugorasol-for-priority-review.html
About Author
Saipriya Iyer . .
Saipriya Iyer presently works as a content developer for fractovia.org. Having dabbled with the domain of content creation for nearly half a decade, she now boasts of an enviable portfolio, holding substantial experience in penning down pieces related to technology, finance, and a wide spectrum of other industry verticals. A qualified computer engineering graduate from the University of Pune, Saipriya can often be found leveraging her knowledge of software technology and electronics in her write-ups. She can be contacted at- [email protected] | https://twitter.com/saipriya_i
Related News
Hero MotoCorp under investigation by Ministry of Corporate Affairs
The Indian Ministry of Corporate Affairs has reportedly ordered a probe into Hero MotoCorp to examine its association with an external vendor regarding alleged fund diversion. The objective of the investigation, conducted in the "public interest," is to evaluate the Hero MotoCorp owners... Read More>>
UK: Residents receive bills of up to £49,000 after Ovo acquires SSE
Customers of Ovo, the energy supplier were reportedly left shocked when they received energy bills of up to £49,000, due to data errors that led to overinflated energy bills for some residents. Ovo accepted that some of its customers have been affected by erroneous meter readings, and it bl... Read More>>
Bob Iger returns to Disney as CEO less than a year post retirement
Bob Iger, the ex-CEO of Walt Disney Co., is reportedly coming back to the mass media giant less than a year after his retirement. The surprise announcement comes at a time when Disney is struggling to earn profits from its streaming TV services. According to a statement released by Disney late Su... Read More>>